Both drinking and withdrawal from chronic drinking can raise circulating glucocorticoid levels, known as cortisol in humans and corticosterone in rodents. Prolonged and high concentrations of glucocorticoids can have damaging effects on neuronal function and cognition. Evidence shows that glucocorticoids are associated with neurotoxicity during abstinence after withdrawal from alcohol dependence (AD), and that glucocorticoid receptor antagonism may represent a pharmacological option for recovery.
A review of this evidence will be published in the December 2010 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.
"Prolonged and elevated levels of glucocorticoid hormones can damage or destroy neurons, and lead to an increased vulnerability to other situations that can damage neurons, such as raised excitatory amino acid activity," explained A.K. Rose, a lecturer in psychology at the University of Liverpool and corresponding author for the review. "This can underlie loss of memory functions."
"High levels of brain cortisol associated with stress have long been linked to deficits in neuronal function, which can be seen in aging," added John Littleton, a professor in the department of pharmaceutical sciences at the University of Kentucky.
Among the review's key points:
- Brain glucocorticoid concentrations increase and glucocorticoid receptor occupancy decreases during prolonged abstinence after withdrawal from alcohol.
"Our evidence shows that brain concentrations of corticosterone remain raised for long periods after alcohol withdrawal, even after the blood concentrations return to normal levels," said H.J. Little, a professor in addiction science at King's College London and who conducted this research. "Furthermore, the corticosterone concentrations remained increased in rodent brains for up to two months, approximately five human years, following cessation of prolonged alcohol drinking."
"One of the most important questions for research and treatment is why alcoholics can relapse after many months of abstinence," observed Littleton. "Partly this can be attributed to the effects of conditioning in which 'cues' provoke craving for alcohol, as well as a 'protracted withdrawal syndrome' which includes anxiety, sleep disturbances, and general feelings of being unwell. Prolonged high levels of brain cortisol after withdrawal from alcohol may explain the strength of these cues, and many of the symptoms of protracted withdrawal."
- Increased glucocorticoid levels in the brain after alcohol treatment are associated with cognitive deficits seen during abstinence, affecting both treatment efficacy and quality of life.
"Cessation of drinking is clearly linked to cognitive deficits," said Little. "For example, visuospatial learning can be worse in abstinent alcoholics than in those still intoxicated, and memory and learning deficits have been found in rats after alcohol withdrawal, but not during alcohol intake. Furthermore, greater neuronal degeneration has been reported after cessation of chronic alcohol intake than during its consumption, and multiple withdrawal episodes cause greater neuronal damage than a single withdrawal episode."
"This point is important because cognitive deficits in alcoholics during attempted abstinence can interfere with treatment options such as 'cognitive behavior therapy' and also drug treatment," said Littleton. "Drugs targeting the effects of cortisol in the brain might therefore both reduce the chances of relapse and reduce the cognitive deficits that interfere with treatment."
- Glucocorticoids are involved in the neuropathological consequences of AD.
"Animal and cell-culture research show very convincingly that cortisol/corticosterone can increase neurotoxicity associated with periods of alcohol withdrawal," said Littleton. "Since the highest cortisol levels were found in the prefrontal cortex and hippocampus, this may explain why these areas are damaged in alcoholics. This makes the brain cortisol glucocortcoid receptors a potential target for prevention of alcohol-induced brain damage."
"If cognitive impairments could be reduced, patients would be more likely to engage in, and thus benefit from, psychosocial treatments," added Rose. "Better cognitive function coupled with better treatment engagement is likely to produce better treatment outcomes and quality of life. A person with greater cognitive function is likely to be more able to find work and re-build relationships.
"In summary," said Littleton," stress, the hypothalamo-pituitary adrenal axis, and cortisol are very important determinants of the natural history of alcoholism -- affecting an individual's drinking behavior, the effects on cognition and memory, and the likelihood of relapsing into alcoholism during abstinence. We can also see that hypotheses applicable to animals can now be applied to inform new human research."
Alcoholism: Clinical & Experimental Research (ACER) is the official journal of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism. Co-authors of the ACER paper, "The Importance of Glucocorticoids in Alcohol Dependence and Neurotoxicity," were: S.G. Shaw of the Department of Clinical Pharmacology and Clinical Research at the University of Bern; M.A. Prendergast of the Department of Psychology in the Spinal Cord and Brain Injury Research Center at the University of Kentucky; and H.J. Little of the Division of Psychological Medicine and Psychiatry in the Institute of Psychiatry at King's College London, and the Departments of Basic Medical Sciences and Mental Health at the University of London. The study was partly funded by the National Institute on Alcohol Abuse and Alcoholism. This release is supported by the Addiction Technology Transfer Center Network at http://www.ATTCnetwork.org.
Add'l Contact: H.J. Little, Ph.D. firstname.lastname@example.org 44.207.848.0436 (England) King's College London
- A. K. Rose, S. G. Shaw, M. A. Prendergast and H. J. Little. The Importance of Glucocorticoids in Alcohol Dependence and Neurotoxicity. Alcoholism: Clinical & Experimental Research, 7 SEP 2010 DOI: 10.1111/j.1530-0277.2010.01298.x
Cite This Page: